ANTIPODES PARTNERS Ltd Purchases 33,170 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

ANTIPODES PARTNERS Ltd grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 16.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 238,749 shares of the biopharmaceutical company's stock after purchasing an additional 33,170 shares during the period. Alnylam Pharmaceuticals makes up 2.2% of ANTIPODES PARTNERS Ltd's portfolio, making the stock its 22nd biggest holding. ANTIPODES PARTNERS Ltd owned 0.19% of Alnylam Pharmaceuticals worth $59,432,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Allspring Global Investments Holdings LLC lifted its stake in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 143 shares in the last quarter. Altitude Crest Partners Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter worth approximately $30,000. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 12,513 shares during the period. V Square Quantitative Management LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $52,000. Finally, Benjamin F. Edwards & Company Inc. acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $71,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the firm's stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at $20,563,480. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the sale, the director now directly owns 136 shares in the company, valued at approximately $30,013.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares of the company's stock, valued at $20,563,480. The disclosure for this sale can be found here. In the last ninety days, insiders sold 103,148 shares of company stock valued at $25,658,824. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded down $4.70 during trading hours on Friday, hitting $246.78. 682,405 shares of the company's stock were exchanged, compared to its average volume of 903,035. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $287.55. The stock has a market cap of $31.22 billion, a price-to-earnings ratio of -93.84 and a beta of 0.37. The stock's 50-day moving average is $257.28 and its 200-day moving average is $190.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The company's revenue was up 107.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.21) earnings per share. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on ALNY shares. Citigroup increased their price objective on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. Cantor Fitzgerald increased their price target on shares of Alnylam Pharmaceuticals from $150.00 to $220.00 and gave the stock a "neutral" rating in a research note on Monday, July 22nd. Bank of America lifted their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the company a "buy" rating in a research note on Wednesday. Leerink Partners increased their price objective on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a "market perform" rating in a report on Tuesday, June 25th. Finally, Needham & Company LLC raised their price target on Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. Seven analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $279.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.